Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes

doi:10.3748/wjg.v23.i6.1059

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 6

This Article

(490)

(412)

(0)

(8648)

(15)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Study

World J Gastroenterol. Feb 14, 2017; 23(6): 1059-1066
Published online Feb 14, 2017. doi: 10.3748/wjg.v23.i6.1059

Table 1 Baseline characteristics of the patients n (%)

Variable	Patients (n = 636¹)
Age (yr, mean ± SD)	54.6 ± 11.6
Gender
Male	354 (55.7)
Female	282 (44.3)
Residence
Rural	126 (19.8)
Urban	510 (80.2)
Cigarette smoking	174/605 (28.8)
Alcohol intake	279/605 (46.1)
Diabetes mellitus	61/605 (10.1)
Hypertension	121/605 (20.0)
Endoscopic findings
Gastric ulcer	205 (32.2)
Duodenal ulcer	193 (30.3)
Gastric ulcer + Duodenal ulcer	40 (6.3)
Post ESD due to adenoma or EGC	91 (14.3)
Nodular gastritis	29 (4.6)
Others²	78 (12.2)

¹Total number of enrolled patients; missing values are not included. The number behind the dash is the total number of subjects who answered each question.

²Others include MALT lymphoma, dyspepsia, gastric polyp and intestinal metaplasia. ESD: Endoscopic submucosal dissection; EGC: Early gastric cancer; MALT lymphoma: Mucosa-associated lymphoid tissue lymphoma.

Full Size Table

Citation: Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066
URL: https://www.wjgnet.com/1007-9327/full/v23/i6/1059.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i6.1059

Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.